Objective-Recently, we have demonstrated that acute glucosamine-induced augmentation of protein O-linked β-Nacetylglucosamine (O-GlcNAc) levels inhibits inflammation in isolated vascular smooth muscle cells and neointimal formation in a rat model of carotid injury by interfering with NF-κB (nuclear factor-κB) signaling. However, the specific molecular target for O-GlcNAcylation that is responsible for glucosamine-induced vascular protection remains unclear.
P
rotein O-GlcNAcylation is a functionally important posttranslational modification of serine/threonine residues by O-linked β-N-acetylglucosamine (O-GlcNAc). 1 Although sustained increases in O-GlcNAc have been implicated as a pathogenic contributor to glucose toxicity and insulin resistance, there is accumulating evidence that acute increases in O-GlcNAc levels elicit cellular protection designed to enhance cell survival. [2] [3] [4] We have demonstrated that a single injection of glucosamine or the O-linked N-acetylglucosaminidase inhibitor O-(2-acetamido-2-deoxy-D-glucopyranosylidene) amino N-phenyl carbamate (PUGNAc) increased O-GlcNAcylation levels in balloon-injured rat carotid arteries, leading to significant inhibition of neutrophil and monocyte infiltration and proinflammatory cytokine expression in the injured artery. Further, chronic (14 days) treatment with glucosamine reduces neointimal formation in injured arteries compared with vehicle treatment. 5 These results suggest that augmenting protein O-GlcNAcylation in the vasculature may be a novel anti-inflammatory and vasoprotective mechanism. However, the key targets of O-GlcNAcylation in this setting remain unclear.
The transcription factor NF-κB (nuclear factor-κB) plays a critical role in the regulation of inflammatory signaling and innate and adaptive immunity. 6 NF-κB activation is central
The zinc-finger protein A20 has been implicated in the control of inflammation, regulation of the innate and adaptive immune system, and TNF-α (tumor necrosis factor-α)-induced apoptosis. 9 For example, deficiency of A20 in mice is associated with hypersensitivity to TNF-α and leads to premature death because of severe multiorgan inflammation and cachexia. 10 Polymorphisms in the A20 locus are associated with multiple autoimmune diseases, including systemic lupus erythematosus, and A20 has been identified as a tumor suppressor in B-cell lymphoma. 11 Given the central role of ubiquitination in NF-κB signaling pathways, it is not surprising that deubiquitinase plays a critical role in the inhibition of NF-κB signaling. Utilizing its deubiquitinase activity, A20 specifically removes Lys63 polyubiquitin chains from NEMO (NF-κB essential modulator), TRAF6 (TNF receptor-associated factor 6), and RIP1/2 (receptor-interacting protein 1/2) to suppress NF-κB activation. Further, the C-terminal domain of A20, composed of 7 C2/C2 zinc fingers, functions as a ubiquitin ligase and mediates Lys48 ubiquitination of RIP1, thereby targeting RIP1 for proteasomal degradation. 12 Although the inhibitory effect of A20 on the NF-κB signaling cascade has been extensively studied, the regulation of A20 activity remains poorly understood. At the transcriptional level, A20 expression can be rapidly induced in response to many stimuli that trigger the binding of NF-κB to its promoter. At the protein level, several A20-binding proteins such as ABIN (A20-binding inhibitor of NF-κB) and TAX1BP1 (Tax1-binding protein 1) are involved in the regulation of A20 activity by the formation of a complete ubiquitin-editing functional complex. 13 There is little evidence that post-translational modifications, including phosphorylation and ubiquitylation, either support or restrict the activity of A20, and it is not known whether protein O-GlcNAcylation regulates A20 activity. In this study, we test the hypothesis that A20 O-GlcNAcylation is required for glucosamine-mediated anti-inflammatory effects and vascular protection.
Materials and Methods

Rat Vascular Smooth Muscle Cells Culture
Primary cultures of vascular smooth muscle cells (VSMCs) were derived from 10-week-old male Sprague-Dawley rats, as we previously described.
14 All protocols were approved by the Ethical Committee of the University of Yangzhou. Cells were cultured in complete medium containing phenol red-free DMEM (Gibco) supplemented with 10% fetal bovine serum, 4 mmol/L l-glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin. VSMCs were used within 3 to 4 passages. Our immunofluorescence staining with several specific antibodies, including anti-Myh10 (sc-33729; Santa Cruz), anti-Myh11(ab53219), anti-α-SMA (ab5694; Abcam), and antismoothelin B (NBP2-37931; Novus Biologicals) showed that most cells in the culture system are dedifferentiated smooth muscle cells (SMCs), which are characterized by high expression levels of Myh 10 (myosin heavy chain 10), but much weaker staining for Myh 11, α-SMA (α-smooth muscle actin), and smoothelin B ( Figure I in the online-only Data Supplement).
Adenoviral Vector Generation
To increase A20 expression, a pEGFP-A20 plasmid was obtained from Addgene (plasmid number 22141). Human TNFAIP3 cDNA was subcloned into the adenovirus shuttle plasmid vector pAV.ExBi-CMV, which contains a cytomegalovirus promoter. Recombinant adenovirus carrying the human TNFAIP3 gene (pAV.ExBi-CMVhTNFAIP3-IRES-eGFP, Ad-A20) was generated by homologous recombination by Cyagen Bioscience, Inc (Guangzhou, China). An adenovirus containing empty vector with an eGFP (enhanced green fluorescent protein) tag served as a control (Ad-null). To knockdown endogenous A20 expression, 3 pair-specific shRNAs (shRNA1: GCC  CAC AGT TTC GAG AGA TCA CTC GAG TGA TCT CTC GAA  ACT GTG GGC; shRNA2: GGA GTG GAC TTC AGT ACA ATT  CTC GAG AAT TGT ACT GAA GTC CAC TCC; and shRNA3:  GCA GTG AGG AAC TCT GTA TGG CTC GAG CCA TAC AGA  GTT CCT CAC TGC) for the rat TNFAIP3 gene were designed by Cyagen Bioscience Inc (Guangzhou, China). For adenovirus preparation, plasmids were recombined with the pAV.KdSi.U vector using the Cyagen Adenoviral Expression System (Cyagen). An alternative adenovirus construct containing a scramble shRNA shown not to interfere with TNFAIP3 was used as a control. Large-scale amounts of recombinant adenovirus were amplified in 293 cells and purified. Viral titers were determined by a plaque assay on a 293 cell monolayer. Experiments were conducted at 100 multiplicity of infection for both viruses. After 4 hours of incubation, media were removed, and cells were incubated in appropriate media for 72 hours.
Western Blotting Analysis
Protein samples were extracted from VSMCs and carotid arteries with lysis buffer. Protein concentration was determined by a Bradfordbased method (Bio-Rad). All samples were separated on 10% SDS-PAGE and transferred to a polyvinylidene difluoride membrane as described previously. 15 Blots were probed with anti-A20 (4625; Cell Signaling Tech), anti-p-p65 (3033; Cell Signaling Tec), anti-IκBα (inhibitor of κBα; ab32518; Abcam), anti-p65 (ab16502; Abcam), anti-GAPDH (sc-47724; Santa Cruz) primary antibodies with working concentration about 1 μg/mL and a horseradish peroxidase-conjugated secondary antibody, respectively. Bands were visualized by use of a Super Western Sensitivity Chemiluminescence Detection System (34578; Pierce). Autoradiographs were quantified by densitometry (NIH Image J). 
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Chromatin Immunoprecipitation Analysis
Chromatin immunoprecipitation (ChIP) assays were performed as previously described. 15 Briefly, quiescent VSMCs were pretreated with 300 nmol/L thiamet G (SML0244; Sigma Aldrich) or vehicle and then treated with 10 ng/mL TNF-α (T6674; Sigma Aldrich). After 1 hour, cells were fixed and nuclear protein-DNA complexes were extracted and subjected to ChIP analysis using anti-p65 (ab16502; Abcam) antibody and normal rabbit IgG (sc-2027; Santa Cruz). A pair of primers (5′-GTG CTG ACC CCA ATA AGG AA-3′ and 5′-TGC TGA AGT CCT TAG GGT TGA-3′) was used to amplify the promoter region of the rat MCP-1 (monocyte/macrophage chemotactic protein-1) gene for detection of binding of p65 using real-time reverse transcription polymerase chain reaction (RT-PCR) with SYBR green reagent (4367659; Applied Biosystems, CA) using an ABI PRISM 7500 sequence detection system (Applied Biosystems). For analysis, a 
Quantitative Real-Time RT-PCR
Total RNA was extracted from VSMCs using TRIzol reagent (15596-026; Invitrogen) and reverse transcribed to cDNA. cDNA was amplified by real-time quantitative polymerase chain reaction using the SYBR green (4367659; Applied Biosystems) in an ABI PRISM 7500 sequence detection system (Applied Biosystems) with specific primers for rat TNFAIP3 gene (forward: 5′-AAG TGG GTG GGA TCT ACC TG-3′ and reverse: 5′-CTG ACT GTC GTA GCC AAG GA-3′); MCP-1 gene (forward: 5′-ATG CAG GTC TCT GTC ACG CT-3′, reverse: 5′-GGT GCT GAA GTC CTT AGG GT-3′); P-selectin gene (forward: 5′-AAT GAA ATC GCT CAC CTC-3′, reverse: 5′-TTA TTG GGC TCG TTG TCT-3′) or GAPDH gene (forward: 5′-GTT GTC TCC TGC GAC TTC A-3' and reverse: 5'-GTG GTC CAG GGT TTC TTA CT-3') as described previously. Levels of target gene mRNAs were normalized using GAPDH mRNA and then standardized to the mRNA level of vehicle-treated VSMCs.
NF-κB Activity Measurement
Nuclear protein was isolated from VSMCs using the Nuclear and Cytoplasmic Extraction reagents (NE-PER) kit (78835; Pierce). NF-κB DNA binding activity was measured using the TransAM NFκB p65 transcription factor assay kit according to the manufacturer's instructions (40098; Active Motif, Carlsbad, CA).
Rat VSMCs Migration Analysis
Serum-starved rat VSMCs (0.5×10 5 ) infected with Ad-A20, Ad-A20 shRNA, or Ad-scramble shRNA were seeded in Falcon cell culture inserts (35-3097; Becton Dickinson Labware) with 8.0-μm pore size in 1% fetal bovine serum-DMEM with vehicle or 300 nmol/L thiamet G. After incubation for 1 hour, cells were treated with vehicle or TNF-α (10 ng/mL) for 12 hours; the cells in the upper chamber and on the polyester-track-etched membrane were mechanically removed with a cotton swab and washed with ice-cold PBS. Cells adherent to the outer surface of the lower side of the membrane were fixed with methanol for 15 minutes and stained with hematoxylin for 20 seconds. Fifteen fields were randomly selected in each group, and cells were counted.
Cell Proliferation
VSMCs proliferation was measured by using Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan). Rat VSMCs infected with Ad-A20, Ad-A20 shRNA, or Ad-scramble shRNA were seeded in 96-well plates at ≈1.5×10
4 cells per well and cultured in 1% fetal bovine serum-DMEM containing 300 nmol/L thiamet G. After 1 hour, cells were treated with vehicle or TNF-α (10 ng/mL) for 24 hours, following which 10 μL of the CCK-8 solution were added to each well, and incubation was continued for 2 hours. Cell numbers were measured in triplicate using a 96-well format plate reader (Bio-Rad 680 microplate Reader). Absorbance of the dye with a wavelength of 450 nm (OD450) was obtained, which was proportional to the number of live cells.
Rat Carotid Artery Balloon Injury Model
Adult male Sprague-Dawley rats (8-10 weeks) that weighed 300 to 350 g were obtained from the Comparative Medical Center of Yangzhou University (China) and maintained at constant humidity (60±5%), temperature (24±1°C), and light cycle (6:00 am to 6:00 pm) and fed a standard rat pellet diet ad libitum. To exclude the protective effect of estrogen on vascular injury, adult male rats were used in this study. Rats were randomized to receive daily injections of glucosamine (0.3 mg/g per day, IP; 1294207, Sigma Aldrich) or vehicle. Two hours after the first injection of glucosamine, rats were anesthetized with 80 mg/kg ketamine and 5 mg/kg xylazine and subjected to balloon injury of the right common carotid artery, as previously described. 16 Briefly, the right external carotid artery was exposed, and a 1.5 mm Medtronic balloon angioplasty catheter was inserted, inflated, and advanced and withdrawn 3 times to denude the endothelium and deliver crush injury to the medial SMCs of the artery. The injured segment of artery was then incubated in the Ad-A20 shRNAeGFP or Ad-Scramble shRNA-eGFP (1.0×10 9 plaque-forming unit) in a total volume of 100 μL saline for 30 minutes. The uninjured left carotid artery served as a control. After surgery, glucosamine was administered daily in the same dose for 14 days.
Rats were euthanized at 14 days after injury with an intraperitoneal injection of pentobarbitol (100 mg/kg). The balloon-injured segment of the artery from the proximal edge of the omohyoid muscle to the carotid bifurcation was perfused with saline and dissected. The tissue was then fixed with 100% methanol and embedded in paraffin. Histological images of 4-μm cross-sections from the center of the injured segment were hematoxylin eosin stained and used to determine the intimal, medial, and luminal areas by quantitative morphometric analysis. Three sections from each artery were evaluated by an investigator who was blinded to the identities of the treatment groups. All protocols were approved by the Institutional Animal Care and Use Committee of Medical College of Yangzhou University and were consistent with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication, 8th Edition, 2011).
Immunochemistry and Immunofluorescence
For immunochemistry, representative arteries were harvested 14 days after vascular injury and fixed in paraformaldehyde and paraffin embedded. To determine the leukocyte infiltration in the vessels, the standard immunohistochemical technique was used to detect neutrophils and microphage in paraffin-embedded sections of carotid artery. Briefly, deparaffinized and hydrated sections were quenched with 3% hydrogen peroxide and digested with compound digestive juice followed by blocking with 5% bovine serum albumin. Tissues were then incubated with the primary antibody, including anti-ly6G (ab25377; Abcam), anti-F4/80(ab6640; Abcam), and anti-α-SMA (ab5694; Abcam), overnight at 4°C, respectively. The SABC kit (Boster, Wuhan, China) was used for the subsequent steps according to the manufacturer's instructions. Chromogenic development was accomplished using diaminobenzidine-hydrogen peroxide. Slides were then slightly counterstained with hematoxylin and dehydrated, and coverslips were applied. For immunofluorescence, the fluorescein isothiocyanate-conjugated or Texas Red-conjugated streptavidin second antibodies were used. To reveal nuclei, we treated each tissue section with 4′-6-diamidino-2-phenylindole (D4592; Sigma Aldrich). These sections were viewed with a Nikon Ti-U inverted epifluorescence microscope equipped with appropriate filters (Nikon) at a ×100 magnification, and 5 randomly selected fields from each slide were analyzed.
Statistical Analysis
Results were expressed as mean±SEM. Analyses were performed using the SPSS software version 11.0 for Windows (SPSS, Inc, Chicago, IL). Shapiro-Wilk normality test was used for checking the normality of the data. Comparison between 2 groups was evaluated with 2-tailed independent Student t test. Comparison among >2 groups was evaluated by a 1-way or 2-way ANOVA with the Bonferroni correction for multiple pairwise comparisons. A P value <0.05 was considered statistically significant.
Results
Increasing Intercellular Protein O-GlcNAcylation Level Promotes A20 O-GlcNAcylation in VSMCs
To test whether A20 can be subjected to O-GlcNAc modification, VSMCs were pretreated with vehicle, 5 mmol/L glucosamine, the specific O-linked N-acetylglucosaminidase inhibitor PUGNAc (0.1 μmol/L), or thiamet G (300 nmol/L) for 2 hours, respectively, then challenged with 10 nmol/L TNF-α for 6 hours. The cellular extracts were immunoprecipitated with anti-O-GlcNAc-specific antibody 18B10.C7 (Millipore), followed by Western blotting with an anti-A20-specific antibody. We found that either increasing the production of UDPGlcNAc (uridine diphosphate N-acetylglucosamine) with glucosamine or inhibiting O-linked N-acetylglucosaminidase by PUGNAc/thiamet G significantly increased the level of O-GlcNAcylated A20 ( Figure 1A) . We also performed reciprocal Co-IP with anti-A20 and used anti-O-GlcNAc for immunoblotting and found that either glucosamine or PUGNAc/ thiamet G treatment increased the level of A20 O-GlcNAc modification ( Figure 1B) . Similarly, we also observed that infecting an adenovirus carrying O-linked GlcNAc transferase could increase A20 O-GlcNAcylation. By contrast, O-linked N-acetylglucosaminidase overexpression significantly inhibited thiamet G-induced A20 O-GlcNAcylation ( Figure II in the online-only Data Supplement). Together, the results suggest that A20 was O-GlcNAcylated in VSMCs.
Thiamet G Treatment Regulates A20 Activity by Increasing Binding to TAX1BP1 in VSMCs
To test whether increasing protein O-GlcNAc level affects A20 activity, we first tested the effect of thiamet G on A20 expression in VSMCs. Cells were pretreated with 300 nmol/L thiamet G for 2 hours and then treated with TNF-α for 0 to 6 hours. Quantitative RT-PCR showed that A20 mRNA was significantly increased in response to TNF-α treatment and that thiamet G treatment further increased TNF-α-induced expression of A20 mRNA. However, thiamet G pretreatment did not alter TNF-α-induced A20 protein expression compared with vehicle ( Figure  IIIA and IIIB in the online-only Data Supplement). Further, we found that thiamet G treatment significantly increased A20 ubiquitination in VSMCs ( Figure IIIC in the online-only Data Supplement). Therefore, thiamet G treatment did not upregulate A20 expression, which may be because of an increase in A20 proteasomal degradation in VSMCs.
Because the adaptor protein TAX1BP1 plays a role in the regulation of A20 activity through providing substratespecific recognition of A20 protein and assembling a functional A20 ubiquitin-editing complex, we next tested whether thiamet G treatment regulated the interaction between A20 and TAX1BP1. As shown in Figure 2 , coimmunoprecipitation analysis showed that TNF-α treatment stimulated A20 binding to TAX1BP1. Thiamet G treatment also significantly increased the interaction between A20 and TAX1BP1 proteins in vitro. These results suggest that augmenting intracellular protein O-GlcNAcylation enhances A20 activity mainly by increasing its interaction with TAX1BP1, not by increasing the level of A20 protein expression.
Thiamet G Enhances A20-Induced Inhibition of IκBα Degradation and p65 Activation in VSMCs
To test the effect of A20 O-GlcNAcylation on inhibition of the NF-κB signaling pathway, VSMCs were infected with an adenovirus carrying A20 (Ad-A20) or an adenovirus carrying an empty vector (Ad-null) for 3 days. Cells were pretreated with vehicle or thiamet G for 2 hours and then stimulated with TNF-α for 30 minutes. In the cells infected with Ad-null, TNF-α rapidly induced IκBα degradation. In contrast, overexpression of A20 significantly attenuated the degradation of IκBα-induced by TNF-α. Interestingly, we found that thiamet G treatment further prevented the degradation of IκBα in cells infected with Ad-A20 ( Figure 3A) . Overexpression of A20 also inhibited TNF-α-induced p65 phosphorylation at Ser536 compared with Ad-null. Thiamet G treatment further enhanced the inhibitory effect of A20 on p65 activation in cells infected with Ad-A20 compared with vehicle treatment ( Figure 3B ).
A20 O-GlcNAcylation Enhances the Inhibitory Effect of A20 on NF-κB DNA Binding Activity in VSMCs
To examine the effect of A20 O-GlcNAcylation on inhibition of NF-κB DNA binding activity, p65 DNA binding activity was measured in nuclear protein extracts using a specific ELISA-based NF-κB transcription factor assay. In cells infected with Ad-null, TNF-α-induced p65 DNA binding activity was significantly increased compared with vehicle controls. Transfection of Ad-A20 significantly impaired TNF-α-induced NF-κB activation compared with Ad-null. Importantly, we also observed that pretreatment with thiamet G further enhanced the inhibitory effect of A20 on TNF-α-induced NF-κB activation compared with vehicle in cells infected with Ad-A20 ( Figure 4A ). The chromatinimmunoprecipitation assay also showed that overexpression of A20 significantly attenuated TNF-α-induced p65 binding to the promoter of MCP-1 (monocyte/macrophage chemotactic protein-1) compared with the empty vector. Increasing protein O-GlcNacylation with thiamet G further amplified the effect of A20 ( Figure 4B ). These results indicate that O-GlcNAcylation of A20 enhances its inhibitory effect on NF-κB signaling. 
Overexpression of A20 Enhances and Knockdown of A20 Minimizes the AntiInflammatory Effect of Thiamet G in VSMCs
We have demonstrated that increasing protein O-GlcNAc level with glucosamine or PUGNAc significantly inhibits TNF-α-induced proinflammatory cytokine expression in cultured VSMCs. 17 To examine the functional significance of A20 in augmenting this O-GlcNAcylation-mediated antiinflammatory effect, we constructed an adenovirus carrying an A20 shRNA plasmid. Transfection of Ad-A20-shRNA led to a significant decrease in TNF-α-induced A20 expression compared with Ad-scramble shRNA ( Figure IVA and IVB in the online-only Data Supplement). Consistent with our previous results, quantitative real-time RT-PCR showed that thiamet G treatment attenuated TNF-α-induced MCP-1 and P-selectin mRNA expression in cells infected with Ad-null compared with vehicle. However, overexpression of A20 significantly enhanced the anti-inflammatory effect of thiamet G compared with Ad-scramble shRNA, whereas silencing A20 expression increased basal and TNF-α-induced cytokine mRNA expression and nearly completely abolished the antiinflammatory action of thiamet G compared with scramble shRNA ( Figure 5 ). These results provide evidence that the anti-inflammatory effect of thiamet G depends on A20.
Increasing A20 Expression Enhances and Silencing A20 Abolishes the Inhibitory Effect of Thiamet G on TNF-α-Induced Migration and Proliferation of VSMCs
In the setting of balloon injury, medial VSMCs proliferate and migrate toward the lumen in the process of vascular remodeling. We observed that TNF-α-induced migration and proliferation of VSMCs infected with Ad-scramble shRNA were significantly suppressed by thiamet G compared with vehicle controls. Overexpression of A20 by transfection with Ad-A20 significantly enhanced the effects of thiamet G on the migration and proliferation of VSMCs compared with Ad-scramble shRNA. However, A20 knockdown directly promoted SMC migration and proliferation in the absence of TNF-α and further enhanced the effects of TNF-α. In contrast, A20 deficiency effectively abolished the effects of thiamet G on TNF-α-induced cell migration and proliferation ( Figure 6 ).
A20 Knockdown Abolishes the Inhibitory Effect of Glucosamine on Neointimal Formation in the Injured Carotid Artery
To define the role of A20 in glucosamine-induced vascular protection in vivo, adult male rats were treated with glucosamine (0.3 g/kg per day, IP) and then subjected to balloon injury of the carotid artery and local injection of Ad-scramble shRNA, Ad-A20 shRNA, or an equal volume of normal saline, followed by daily injections of equal doses of glucosamine for 14 days. Adenovirus administration led to significant enrichment of GFP staining in the media at 7 days post-injury compared with normal saline, suggesting a high efficiency of adenovirus-mediated local gene transfection ( Figure V in the onlineonly Data Supplement). Glucosamine treatment significantly increased O-GlcNAc levels in injured vessels of all treatment groups at 14 days post-surgery ( Figure VI in the online-only Data Supplement). Morphometric analysis showed that, compared with the sham group, neointimal formation in the balloon-injured groups was significantly increased. Glucosamine administration significantly reduced balloon injury-induced neointimal formation compared with the saline group. A similar inhibitory effect of glucosamine on neointimal formation occurred in rats injected with Ad-scramble shRNA. Interestingly, local delivery of Ad-A20 shRNA significantly attenuated the effect of glucosamine in the prevention of balloon injury-induced neointimal formation (Figure 7 ).
Silencing A20 Enhances VSMCs Accumulation and Increases Proinflammatory Cells Infiltration Into the Neointimal in the Injured Carotid Artery
To address whether A20 O-GlcNAcylation by glucosamine was implicated into regulating VSMCs migration and proinflammatory infiltration in vivo, we used several specific 
Silencing A20 Enhances NF-κB Activation and Increases Expression of Proinflammatory Cytokines in Injured Vessels
To further address the mechanism of glucosamine-induced vascular protection, we also examined p65 activation in the injured vessels. At 14 days after balloon injury, we observed significant upregulation of A20 expression in injured arteries compared with sham controls. Local delivery of Ad-A20 shRNA-eGFP markedly reduced A20 expression in the Ad-A20 shRNA group compared with the other treatment groups, suggesting the feasibility of the local transfection of Ad-A20 shRNA to knockdown endogenous A20 protein in vessels. Interestingly, we also found that p65 phosphorylation in the injured vessels was significantly increased compared with normal vessels from the sham group. In contrast, total p65 expression was unaffected by balloon injury. Glucosamine treatment effectively inhibited balloon-induced p65 activation. More importantly, unlike in the other groups, glucosamine treatment could not inhibit p65 activation in the carotid arteries from the Ad-A20 shRNA group ( Figure 9A  through 9D) . Consistently, real-time RT-PCR showed that glucosamine treatment effectively decreased balloon injuryinduced increases in local proinflammatory cytokines MCP-1 and VCAM-1 (vascular cell adhesion molecule 1) mRNA in injured carotid arteries from NaCl-treated and Ad-scramble shRNA-treated rats compared with vehicle. However, glucosamine failed to suppress proinflammatory cytokine expression in the Ad-A20 shRNA group compared with Ad-scramble shRNA group (Figure 9E and 9F) . These results suggest that deficiency of A20 may abolish the anti-inflammatory effects of glucosamine in the injured vessels.
Discussion
This study has demonstrated that O-GlcNAcylation functions as a key post-translational modification that allows A20 to participate in the negative regulation of NF-κB signaling. More importantly, we have provided evidence to support the critical role of A20 O-GlcNAcylation in vascular protection in vivo by demonstrating that silencing A20 expression nearly completely abrogated glucosamine-mediated attenuation of the neointimal formation and adverse vascular remodeling in a rat model of carotid artery balloon injury. There provocative findings strengthen the notion that acutely increasing protein O-GlcNAcylation might be a novel therapeutic strategy for the prevention of many cardiovascular diseases that have an inflammatory basis.
Ubiquitination of key molecules plays a critical role in the regulation of NF-κB signaling.
18 A20 contains an ovarian tumor deubiquitinase domain and 7 carboxyterminal zincfinger domains, 1 of which functions as an E3 ligase. Once NF-κB is activated, A20 can be directly induced, as a negative feedback loop, to terminate canonical NF-κB activation by deubiquitinating key signaling molecules. The A20 complex targets the E3 ubiquitin ligases TRAF6, TRAF2, and cIAP1/2 (cellular inhibitor of apoptosis 1 and 2) and disrupts their binding with the E2 enzymes Ubc13 and UbcH5c, leading to proteasomal degradation of E2s. 19 The dual ubiquitin-editing capacity during ubiquitination modification provides a diversity of regulatory mechanisms for A20 in the termination of NF-κB activation.
A20 was originally cloned from endothelial cells but is also expressed in a variety of other cell types. Definition of the role of A20 in the regulation of canonical NF-κB and cellsurvival signals has led to establishment of a link between A20 and human disease. For example, clinical studies have shown that the single-nucleotide polymorphisms of TNFAIP3 were associated with increased susceptibility to many immune and inflammation-related diseases, including diabetic vascular disease, rheumatoid arthritis, and Crohn disease, [20] [21] [22] likely through reduction in A20 expression and functional activity. Therefore, targeting A20 expression and functional activity may be a promising strategy in the prevention of the abovementioned diseases. However, the detailed mechanism of A20 activation remains poorly understood.
O-GlcNAcylation, a dynamic post-translational modification of specific serine and threonine residues in many proteins, is involving in gene transcription, protein translation and trafficking, and protein-protein interactions.
1 Accumulating evidence has shown that O-GlcNAcylation of some key molecules, for example, c-Rel, p65, and IKKβ (IκB kinase β), plays a critical role in the regulation of NF-κB signaling. 23, 24 For example, under high-glucose conditions, O-GlcNAcylation of p65 enhances its transcriptional activity in a site-specific manner. 25, 26 We recently observed in cultured VSMCs that both glucosamine and PUGNAc treatment induced p65 O-GlcNAcylation, thus significantly inhibiting TNF-α-induced proinflammatory cytokine mRNA expression. 17 Importantly, these treatments inhibited p65 phosphorylation at Ser 536 and increased IκBα binding to p65. We used a novel commercially available anti-OGlcNAc antibody CTD110.6, which has an advantage over the classic RL2 antibody in that it can be used for Co-IP analysis. We observed that the CTD110.6 antibody immunoprecipitated a variety of O-GlcNAcylated proteins, one of which could be detected by Western blotting with anti-A20. In the reciprocal Co-IP, we used anti-A20 to generate a positive band migrating at 90 kDa that was detected with anti-O-GlcNAc by Western blotting analysis. These results suggest that A20 underwent O-GlcNAc modification in response to thiamet G treatment. However, because A20 does not contain an N-glycosylation consensus motif, we postulate that certain Ser/Thr residues were O-GlcNAcylated. Future studies are needed to identify the Ser/Thr residue (s) that are O-GlcNAcylated in A20.
Previous studies have shown that phosphorylation of the Ser381 residue regulates A20 activity. 27 However, no specific antibody against phosphorylated A20 is commercially available, so it remains unclear whether thiamet G can regulate A20 phosphorylation by increasing O-GlcNAcylation. Because it has been shown that high glucose had no effect on TNF-α-mediated A20 phosphorylation, 28 we hypothesize that O-GlcNAcylation is unlikely to affect phosphorylation of A20 because the amino acid residues that undergo O-GlcNAcylation may differ from those that are phosphorylated.
To address the effect of O-GlcNAcylation on A20 activity, we measured expression of A20 protein and found that thiamet G treatment significantly increased A20 mRNA levels but did not change A20 protein level, suggesting that O-GlcNAcylation may inhibit the translation or increase the degradation of A20. This interpretation is consistent with previous observations that under chronic high-glucose conditions, augmenting protein O-GlcNAcylation significantly increased A20 ubiquitination and thus promoted to A20 proteasomal degradation.
28 A20 requires TAX1BP1, ITCH (also known as AIP4, atrophin-1-interacting protein 4), and RNF11 (ring finger protein 11) to terminate NF-κB activation in TNFR (TNF receptor) and TLR4 (Toll-like receptor 4) signaling pathways by the formation of a functional ubiquitin editing enzyme complex. 29 Thus, deficiency of TAX1BP1 leads to a persistent activation of NF-κB signaling in TNF-α-treated mouse embryonic fibroblasts. 30 Therefore, in addition to expression of A20, the interaction between A20 and the adaptor molecules during assembly of the ubiquitin-editing complex functions as a key regulatory mechanism of A20 activity. Although thiamet G had no effect on A20 protein expression, it significantly increased A20 binding to TAX1BP1 independent of TNF-α stimulation. These results demonstrate that increasing binding to TAX1BP1 may be an essential mechanism by which protein O-GlcNAcylation modulates A20 activity.
In most unstimulated cells, NF-κB composed of p65 and p50 that remain inactive and bound to the inhibitor IκB in the cytosol. In response to various stimuli such as TNF-α, activated IKK complexes induce IκB phosphorylation and proteasomedependent degradation, which leads to release of p65 and p50 that translocate into the nucleus and induce expression of target genes. We have demonstrated that glucosamine or PUGNAc treatment significantly increases p65 binding to IκBα and thus contributes to inhibition of p65 activation in response to TNF-α in VSMCs. 17 Consistent with previous studies, 31 we observed that overexpression of A20 partially inhibited TNF-α-induced IκBα degradation, p65 phosphorylation, and NF-κB DNA binding activity. Interestingly, thiamet G pretreatment further enhanced the effect of A20 overexpression and effectively prevented IκBα degradation, p65 phosphorylation, and NF-κB activation. Our ChIP analysis showed that thiamet G also enhanced the inhibitory effect of A20 in preventing TNF-α-induced p65 binding to the MCP-1 gene promoter, suggesting In the merged image, A20 + /F4/80 + and A20 + /Ly6G + doublestained cells indicated that A20 was expressed in the inflammatory cells and glucosamine (GlcN) treatment significantly inhibited the inflammatory cells infiltration in the neointimal in the injured vessels. Local delivery of Ad-A20 shRNA effectively silenced the endogenous A20 expression, whereas GlcN failed to inhibit proinflammatory cells infiltration in the injured vessels. Note that the elastic laminae are autofluorescent in the red and green channels. a synergistic effect of A20 and thiamet G on the inhibition of NF-κB activation in TNF-α receptor signaling.
We recently reported that augmenting protein O-GlcNAc level with glucosamine or PUGNAc effectively inhibited proinflammatory cytokine expression in cultured VSMCs. 17 Previous studies have shown that inhibition of NF-κB activation by A20 overexpression suppresses expression of NF-κB target genes, including MCP-1, P-selectin, E-selectin, ICAM-1, IL-8, VCAM-1, IL-6, GM-CSF, and so on. 9 To directly address the effect of A20 on augmenting the anti-inflammatory action of O-GlcNAcylation, we explored the influence of A20 deficiency on thiamet G-mediated inhibition of inflammation in VSMCs. We observed that thiamet G significantly enhanced the inhibitory effect of A20 overexpression on TNF-α-induced MCP-1 and P-selectin mRNA expression, whereas silencing A20 by transfection of Ad-A20 shRNA completely abolished the anti-inflammatory effect of thiamet G in VSMCs. These findings suggest that A20 plays a critical role in the anti-inflammatory effect of acute protein O-GlcNAcylation.
Adult VSMCs are the predominant cell type in the medial zone of blood vessels and have a remarkable capacity for phenotypic plasticity. In response to vascular injury and extracellular signals such as growth factor stimulation, the resident medial differentiated VSMCs readily switch from a static contractile phenotype to an active synthetic state (ie, dedifferentiated), characterized by reduced expression of contractile proteins such as α-SMA, smoothelin, smooth muscle myh11 (myosin heavy chain 11), and increased expression of SMC synthetic gene nonmuscle myosin heavy chain (myh10). Previous studies have shown that cultured SMCs and neointimal SMCs lose expression of contractile proteins. 32 We confirmed that most of the passage 3-4 VSMCs are dedifferentiated SMCs that resemble neointimal cells that appear after vascular injury. It is well accepted that VSMC activation and phenotypic switching are critical for development of the neointimal after vascular injury because migration and proliferation of VSMCs contribute to vascular remodeling processes. [33] [34] [35] [36] A20 has been shown to markedly inhibit TNF-α-induced proliferation and migration of VSMCs through blocking PI3K (phosphoinositide 3-kinase)/Akt/GSKβ (glycogen synthase kinase-beta)-dependent activation of CREB (cAMP response element-binding protein) and increasing expression of the cyclin-dependent kinase inhibitors p21waf1 and p27kip1. 37, 38 Therefore, we examined the interplay between A20 and thiamet G in the regulation of rat VSMC migration and proliferation. We observed that augmenting protein O-GlcNAc levels with thiamet G significantly inhibited TNF-α-induced proliferation and migration of VSMCs and that the antimigratory and antiproliferative activities of A20 were further enhanced by thiamet G. In contrast, the role of thiamet G was abrogated in cells with deletion of A20 by transfection of Ad-A20 shRNA.
Although VSMCs are widely accepted as the major contributor to vascular remodeling post-injury, accumulating evidence has shown that inflammatory cells such as macrophages and neutrophils, as well as some adventitial progenitor stem cells, play important roles in the remodeling process. [39] [40] [41] For example, previous studies showed that Sca1 + cells are located in the adventitia and can be differentiated into smooth muscle-like cells in vitro and that adventitial cells play a role in neointimal formation. 42 In this study, we observed that, similar to the increase in A20 expression in VSMCs after vascular injury, A20 expression also increased in inflammatory cells in response to balloon injury. Interestingly, we observed that local delivery of Ad-A20 Figure 9 . Effect of A20 deficiency on the inhibitory effect of glucosamine (GlcN) on balloon injury-induced NF-κB (nuclear factor-κB) activation in injured arteries. At 14 d after balloon injury, total protein was extracted from the injured arteries. A through D, Levels of phosphorylated p65, total p65, and A20 expression were determined by Western blotting analysis. GAPDH served as an internal control (E and F). Levels of proinflammatory cytokines MCP-1 (monocyte/macrophage chemotactic protein-1) and VCAM-1 (vascular cell adhesion molecule 1) mRNA were measured by real-time reverse transcription polymerase chain reaction. GAPDH mRNA served as an internal control. Results are expressed as mean±SEM, n=6-8. *P<0.05. NS indicates no significance. Statistical analysis: 1-way ANOVA followed by Bonferroni multiple comparison tests.
shRNA effectively infected the VSMCs, inflammatory cells, and adventitial Sca1 + stem cells after vascular injury (Figure IX in the online-only Data Supplement). Because both inflammatory cells and adventitial Sca1 progenitors act as potential targets for Ad-A20-shRNA, we cannot fully exclude the potential beneficial role of A20 O-GlcNAcylation on adventitial cells in the inhibition of neointima formation after balloon injury. Therefore, elucidation of the cell type-specific effects of A20 O-GlcNAcylation-mediated vascular protection will extend our understanding of the vasoprotective role of augmenting protein O-GlcNAcyation in the setting of acute vascular injury.
We recently demonstrated that glucosamine treatment, through increasing overall protein O-GlcNAc levels, effectively prevented balloon injury-induced inflammation, macrophage/neutrophil infiltration, and neointimal formation in rat carotid artery. 5 However, the specific pathways and key mediators responsible for the protective role of glucosamine in this setting remain unclear. Adenoviral delivery of A20 to the balloon-injured rat carotid artery has been shown to effectively prevent neointimal formation by blocking VSMC proliferation, macrophage infiltration, and neovascularization in the adventitia of injured vessels. 37, 38, 43 In addition, A20 has been shown to prevent transplant arteriosclerosis of aorta to carotid allografts by reducing local inflammatory signals. 44 However, the role of A20 in glucosamine-induced vasoprotection in vivo remains unclear.
Activation of the NF-κB pathway is clearly implicated in the response to acute vascular injury in animal models. Because our in vitro data have demonstrated that O-GlcNAcylation plays a critical role in A20-mediated negative regulation of NF-κB activation and VSMC proliferation and migration in response to TNF-α, we hypothesized that A20 is also involved in glucosamine-induced vascular protection in vivo. We have clearly demonstrated that NF-κB activation, that is, p65 phosphorylation, was induced in balloon-injured rat carotid arteries and that glucosamine treatment inhibited p65 phosphorylation but not total p65 expression. We also found that silencing A20 abolished glucosamine-induced inhibition of p65 phosphorylation and nearly completely abrogated the protective role of glucosamine against the injury response. These results provide new evidence that endogenous A20 and its O-GlcNAcylation have an essential role in the modulation of inflammationrelated vascular pathology. Notably, glucosamine can increase production of the O-linked GlcNAc transferase substrate UDP-GlcNAc through the hexosamine biosynthesis pathway to potentiate O-GlcNAcylation in numerous proteins. Thus, A20 may not be a unique target of glucosamine in vivo. Further, we cannot fully exclude an off-target effect of A20-shRNA in the vasoprotective process. Therefore, it is likely that A20 may not be the only mediator of the beneficial effect of glucosamine in the setting of acute vascular injury.
In conclusion, O-GlcNAcylation is a key regulatory mechanism of A20 activity, which in turn plays a role in the negative regulation of the NF-κB signaling cascade, the dominant effector mechanism for glucosamine-induced vascular protection after rat carotid artery balloon injury. These provocative findings provide new insights into prevention of many inflammation-related vascular disorders through O-GlcNAcylation of endogenous vascular A20.
